CME credits: 0.25

Valid until: 30-06-2023

Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-optimizing-treatment-selection-in-relapsed-or-refractory-multiple-myeloma/13823/

Patients with multiple myeloma inevitably experience disease relapse, which is challenging. Rapid therapeutic advances have heralded an increasing number of efficacious targeted strategies and combination therapies for patients after a first relapse or in those with heavily pretreated disease. However, selecting the optimal regimen requires a individualized approach. Hear how Dr. Amrita Krishnan and Dr. Morie Gertz translate the evolving clinical data into their clinical practices and what factors influence their choices to improve durable responses and outcomes for patients with relapsed/refractory multiple myeloma.

=